Unusual cause of right heart failure decompensation in 21-years old patient with idiopathic pulmonary arterial hypertension - A case report;Nietypowa przyciyna zaostrzenia prawokomorowej niewydolności serca u 21-letniej pacjentki z idiopatycznym nadciśnieniem płucnym - Opis przypadku

Pneumonologia i Alergologia Polska

Volumn 75, Issue 1, 2007, Pages 95-99

  Florczyk, Michał ^a,c   Stawecka Pawełczyk, Anna ^a   Kurzyna, Marcin ^a   Fijałkowska, Anna ^a   Burakowski, Janusz ^b   Zyłkowska, Joanna ^a   Szturmowicz, Monika ^a   Wawrzyńska, Liliana ^a   Tomkowski, Witold ^b   Torbicki, Adam ^a  

^a Klinika Chorób Wewn trznych Klatki Piersiowej   (Poland)

^b Zak ad Fizjopatologii Oddychania im Prof Antoniego Koziorowskiego Instytut Gru licy i Chorób P uc w Warszawie   (Poland)

^c INSTYTUT GRU LICY I CHORÓB P UC   (Poland)

Author keywords

Idiopathic pulmonary arterial hypertension; Right heart failure decompensation; Troponin

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76); TROPONIN T; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD; CASE REPORT; FEMALE; HEART FAILURE; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE HYPERTROPHY; HEMOPERITONEUM; HUMAN; PULMONARY HYPERTENSION;

ADULT; BIOLOGICAL MARKERS; FEMALE; HEART FAILURE; HEMOPERITONEUM; HUMANS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; TROPONIN T; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 34347357516     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Humbert M., Morrell N.W., Archer S.L. i wsp. Cellular and molecular pathobiology of pulmonary arterial hypertension. I. Am. Coll. Cardiol. 2004; 43 (supl. S): 13S-24S.
2. Galie N., Torbicki A., Barst R. i wsp. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Eur. Heart J. 2004; 25: 2243-2278.
3. D'Alonzo G.E., Barst R.J., Ayres S.M. i wsp. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 1991; 115: 343-349.
4. Humbert M., Sitbon O., Chaouat A. i wsp. Pulmonary arterial hypertension in France: results from a national registry. Am. J. Respir. Crit. Care Med. 2006; 173: 1023-1030.
5. Badesch D.B., Abman S.H., Ahearn G.S. i wsp. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126 (supl. S): 35S-62S.
6. Roongsritong C., Warraich I., Bradley C. Common causes of troponin elevations in the absence of acute myocardial infarction: incidence and clinical significance. Chest 2004; 125: 1877-1884.
7. Mahajan N., Mehta Y., Rose M. i wsp. Elevated troponin level is not synonymous with myocardial infarction. Int. J. Cardiol. 2006; 111: 442-449.
8. Di Angelantonio E., Florelli M., Toni D. i wsp. Prognostic significance of admission levels of troponin I in patients with acute ischaemic stroke. J. Neurol. Neurosurg. Psychiatry 2005; 76: 76-81.
9. Baillard C., Boussarsar M., Fosse J.P. i wsp. Cardiac troponin I in patients with severe exacerbation of chronic obstructive pulmonary disease. Intensive Care Med. 2003; 29: 584-589.
10. Torbicki A., Kurzyna M., Kuca P. i wsp. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 2003; 108: 844-848.
11. Nagaya N., Nishikimi T., Okano Y. i wsp. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J. Am. Coll. Cardiol. 1998; 31: 202-208.
12. Fijalkowska A., Kurzyna M., Torbicki A. i wsp. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2008; 129: 1313-1321.
13. Andreassen A.K., Wergeland R., Simonsen S. i wsp. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am. J. Cardiol. 2006; 98: 525-529.
14. Leuchte H.H., Baumgartner R.A., Nounou M.E. i wsp. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am. I. Respir. Crit. Care Med. 2006; 173: 744-750.
15. Nagaya N., Nishikimi T., Uematsu M. i wsp. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102: 865-870.
16. Hudson M.P., O'Connor C.M., Gattis W.A. i wsp. Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis. Am. Heart J. 2004; 147: 546-552.
17. Del Carlo C.H., O'Connor C.M. Cardiac troponins in congestive heart failure. Am. Heart J. 1999; 138: 646-653.
18. Pruszczyk P., Kostrubiec M., Bochowicz A. i wsp. N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism. Eur. Respir. J. 2003; 22: 649-653.
19. Rubin L.J., Badesch D.B., Barst R.J. i wsp. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 2002; 346: 896-903.
20. Barst R.J., Langleben D., Badesch D. i wsp. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J. Am. Coll. Cardiol. 2006; 47: 2049-2056.
21. Galie N., Badesch D., Oudiz R. i wsp. Ambrisentan therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2005; 46: 529-535.
22. McLaughlin V.V. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. Eur. J. Clin. Invest. 2006; 36 (supl. 3): 10-15.
23. Sitbon O., McLaughlin V.V., Badesch D.B. i wsp. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 2005; 80; 1025-1030.